Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA

Analog Devices (ADI) and Iovance Biotherapeutics (IOVA) are exhibiting significantly elevated options trading volumes today, each surpassing 50% of their respective average daily share trading volumes. ADI has seen 15,950 contracts trade, with notable activity in the November 2025 $210 put option, while IOVA's 83,690 contracts include substantial volume in the July 2025 $4 call. This heightened options activity indicates unusual directional interest or hedging strategies being deployed in these specific names.

Analysis

Analog Devices (ADI) and Iovance Biotherapeutics (IOVA) are both experiencing unusually high options market activity, with volumes today reaching 50.6% and 50.4% of their respective average daily share volumes. This indicates significant directional positioning or hedging by institutional players. For Analog Devices, the activity is concentrated in the November 2025 $210 strike put options, where 5,525 contracts have traded. Such a large, long-dated put position suggests either a substantial bearish bet on the company's long-term performance or a sophisticated hedging strategy by a major shareholder to protect against a potential price decline below $210. Conversely, Iovance Biotherapeutics is seeing a surge in bullish interest, evidenced by the high volume of 10,183 contracts for the July 2025 $4 strike call option. This concentrated call buying points to strong speculative belief in the company's potential for significant upside over the next year, likely tied to catalysts specific to the biotherapeutics sector. The opposing nature of these large trades—bearish or protective for ADI and overtly bullish for IOVA—highlights distinct investor sentiment and risk assessment for these two companies.

Key Decisions for Investors

• Investors should investigate the catalysts driving the unusual options volume in both ADI and IOVA, as such large, concentrated trades can precede significant stock price movements.